% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pu:272883,
      author       = {Pu, Jingjing and Liu, Ting and Sharma, Amit and Jiang,
                      Liping and Wei, Feng and Ren, Xiubao and Schmidt-Wolf, Ingo
                      G H and Hou, Jian},
      title        = {{A}dvances in adoptive cellular immunotherapy and
                      therapeutic breakthroughs in multiple myeloma.},
      journal      = {Experimental hematology $\&$ oncology},
      volume       = {13},
      number       = {1},
      issn         = {2162-3619},
      address      = {London},
      publisher    = {Biomed Central},
      reportid     = {DZNE-2024-01299},
      pages        = {105},
      year         = {2024},
      abstract     = {The basic idea of modulating the immune system to better
                      recognize and fight tumor cells has led to the successful
                      introduction of adoptive cellular immunotherapy (ACT).
                      ACT-based treatment regimens, in which the patient's own
                      immune cells are isolated and subsequently expanded (ex
                      vivo) and reinfused, have also contributed significantly to
                      the development of a personalized treatment strategy.
                      Complementing this, the unprecedented advances in ACTs as
                      chimeric antigen receptor (CAR)-T cell therapies and their
                      derivatives such as CAR-NK, CAR-macrophages, CAR-γδT and
                      CAR-NKT have further maximized the therapeutic outcomes.
                      Herein, we provide a comprehensive overview of the
                      development of ACTs in multiple myeloma (MM) and outline how
                      they have evolved from an experimental form to a mainstay of
                      standard clinical settings. Besides, we provide insights
                      into cytokine-induced killer cell (CIK) therapy, an
                      alternative form of ACT that (as CIK or CAR-CIK) has
                      enormous potential in the clinical spectrum of MM. We also
                      summarize the results of the major preclinical and clinical
                      studies of adoptive cell therapy in MM and address the
                      current challenges (such as cytokine release syndrome (CRS)
                      and neurotoxicity) that limit its complete success in the
                      cancer landscape.},
      subtyp        = {Review Article},
      keywords     = {CAR-NK (Other) / CAR-T (Other) / CIK (Other) / Cell therapy
                      (Other) / Immunotherapy (Other) / Multiple myeloma (Other)},
      cin          = {AG Ehninger},
      ddc          = {610},
      cid          = {I:(DE-2719)1013005},
      pnm          = {352 - Disease Mechanisms (POF4-352)},
      pid          = {G:(DE-HGF)POF4-352},
      typ          = {PUB:(DE-HGF)16},
      pmc          = {pmc:PMC11514856},
      pubmed       = {pmid:39468695},
      doi          = {10.1186/s40164-024-00576-6},
      url          = {https://pub.dzne.de/record/272883},
}